Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Chem Biol Interact ; 287: 49-56, 2018 May 01.
Article in English | MEDLINE | ID: mdl-29655911

ABSTRACT

Riparin II (RipII) has an anti-inflammatory activity potentially due its ability to decrease TNF-α and IL-1ß production and its histamine antagonism. The objective of this study was to evaluate the role of RipII in the pain process and the possible antinociceptive mechanisms involved, using classic models of nociception. Male Swiss mice were used in the assays. Determinate the acute toxicity according to the OECD 425 test guideline. The models used were the acetic acid-, formalin-, hot plate and glutamate-induced nociception. For evaluation of antinociceptive effect, the involvement of TRPV1, TRPA1, TRPM8, ASICS, Bradykinin, PKC and PKA were performed using the paw licking using agonists. The acute toxicity study did not detect any clinical signs or changes in behavior or mortality. RipII, administered orally (25 and 50 mg/kg) caused a reduction of nociception induced by acetic acid, formalin (on the second phase) and glutamate. In the investigation of antinociceptive mechanism, we used capsaicin (2.2 µg/paw), cinnamaldehyde (10 nmol/paw), menthol (1.2 µmol/paw), ASICS (2% acetic acid, pH 1.98) and bradykinin (10 µg/paw). The results showed that TRPV1, TRPA1, TRPM8, ASICS and bradykinin play a role in the antinociceptive effect of RipII. The results also showed that PKA is involved too. These data demonstrate that RipII has a low or not toxicity and produced an important antinociceptive effect through mechanisms that probably involve an interaction, at least in part, TRPV1, TRPA1, TRPM8, ASICS, bradykinin and PKA participate in the RipII's antinociceptive effect.


Subject(s)
Analgesics/pharmacology , Benzamides/pharmacology , Lauraceae/chemistry , Tyramine/analogs & derivatives , Acid Sensing Ion Channels/metabolism , Alanine Transaminase/blood , Analgesics/therapeutic use , Animals , Aspartate Aminotransferases/blood , Behavior, Animal/drug effects , Benzamides/therapeutic use , Body Weight/drug effects , Bradykinin/metabolism , Creatinine/blood , Cyclic AMP-Dependent Protein Kinases/metabolism , Disease Models, Animal , Lauraceae/metabolism , Male , Mice , Pain/chemically induced , Pain/drug therapy , Pain/pathology , Pain/prevention & control , Protein Kinase C/metabolism , TRPM Cation Channels/metabolism , Tyramine/pharmacology , Tyramine/therapeutic use , Urea/blood
2.
Chem Biol Interact ; 205(2): 148-56, 2013 Sep 25.
Article in English | MEDLINE | ID: mdl-23872152

ABSTRACT

PURPOSE: Our great interest in this work was study the synergism between l-tryptophan and dipyrone or paracetamol as well as the interaction of kynurenic acid (l-tryptophan metabolite) and these analgesics agents utilizing a robust methodology. METHODS: We performed the writhing test induced by acetic acid in mice to evaluate the antinociceptive effect of the treatments isolated and combined (p.o. and i.p.). Dose-response curves were constructed and the values of ED50 for treatment alone and combined were statistically compared. In addition, isobolographic analysis was performed and the experimental values were compared with the theoretical values for simple additive effect. RESULTS: The combined treatment with l-tryptophan and dipyrone or paracetamol reduced significantly the ED50 of these analgesics when compared to the isolated treatments. l-tryptophan alone has no antinociceptive effect. l-Tryptophan increases the central amount of 5-HT and the synergism with dipyrone is antagonized by the 5-HT depletion. The kyna has an antinociceptive dose-related effect and a synergistic interaction with dipyrone and paracetamol verified by isobolographic analyses and confirmed by experimental values of ED50 of combined treatments were statistically lower than theoretical calculated values for simple additive effect. Melatonin antagonist receptor attenuates the antinociceptive synergism between l-tryptophan and dipyrone. CONCLUSION: Our results demonstrate that the increased 5-HT amount on the central nervous system is not per se capable to induce antinociception. The l-tryptophan interacts synergistically with dipyrone and paracetamol both orally and by i.p. route. This effect is dependent on the biotransformation of l-tryptophan to 5-HT and involves kynurenic acid and melatonin receptors.


Subject(s)
Acetaminophen/administration & dosage , Analgesics, Non-Narcotic/administration & dosage , Dipyrone/administration & dosage , Kynurenic Acid/administration & dosage , Tryptophan/administration & dosage , Animals , Dose-Response Relationship, Drug , Drug Synergism , Mice , Pain Measurement/methods , Receptors, Melatonin/antagonists & inhibitors , Tryptamines/administration & dosage
3.
Chem Biol Interact ; 205(3): 165-72, 2013 Oct 05.
Article in English | MEDLINE | ID: mdl-23872256

ABSTRACT

Riparin II (RipII), an alkamide isolated from the green fruit of Aniba riparia, was tested in the various animal models of inflammation to investigate its anti-inflammatory activity. Male Wistar rats (180-240g) were treated with RipII by gavage at doses 25 or 50mg/kg, before initiating the inflammatory responses. The tests used were paw edema induced by carrageenan, dextran, histamine or serotonin; peritonitis induced by carrageenan and fMLP, as well as the measurement of MPO activity, TNF-α and Il-1ß amount in the peritoneal fluid. In the animal models of carrageenan and dextran-induced paw edema, the animals treated with RipII showed lower edema than those of the control group. Treatment with RipII also reduced the paw edema induced by histamine but not serotonin. In the carrageenan-induced peritonitis model, treatment with RipII reduced leukocyte migration, the MPO activity and the amount of TNF-α and IL-1ß in the peritoneal fluid. In summary, these results indicate that RipII has an anti-inflammatory activity in chemical models of acute inflammation. RipII might be directly or indirectly inhibiting the activity, production or release of pro-inflammatory mediators involved in the generation of the pain associated with inflammation.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Benzamides/pharmacology , Inflammation/drug therapy , Tyramine/analogs & derivatives , Animals , Disease Models, Animal , Edema/chemically induced , Edema/drug therapy , Inflammation/chemically induced , Male , Malondialdehyde/metabolism , Mice , Peritonitis/chemically induced , Peritonitis/drug therapy , Rats , Rats, Wistar , Thiobarbituric Acid Reactive Substances/metabolism , Tyramine/pharmacology
4.
Chem Biol Interact ; 203(3): 573-9, 2013 May 25.
Article in English | MEDLINE | ID: mdl-23562495

ABSTRACT

BACKGROUND: Citronellyl acetate (CAT), a monoterpene product of the secondary metabolism of plants, has been shown in the literature to possess several different biological activities. However, no antinociceptive abilities have yet been discussed. Here, we used acute pain animal models to describe the antinociceptive action of CAT. METHODS: The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism. To do so, we induced paw-linking using agonists. RESULTS: CAT was administered intragastrically (25, 50, 75, 100 and 200 mg/kg), and the two higher doses caused antinociceptive effects in the acetic acid model; the highest dose reduced pain for 4h after it was administered (200 mg/kg). In the formalin test, two doses of CAT promoted antinociception in both the early and later phases of the test. The glutamate test showed that its receptors are involved in the antinociceptive mechanism of CAT. Pretreatment with CAT did not alter locomotor activity or motor coordination. In an investigation into the participation of TRP channels and ASICs in CAT's antinociceptive mechanism, we used capsaicin (2.2 µg/paw), cinnamaldehyde (10 mmol/paw), menthol (1.2 mmol/paw) and acidified saline (2% acetic acid, pH 1.98). The results showed that TRPV1, TRPM8 and ASIC, but not TRPA1, are involved in the antinociceptive mechanism. Finally, the involvement of PKC and PKA was also studied, and we showed that both play a role in the antinociceptive mechanism of CAT. CONCLUSION: The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, TRPM8, ASIC, glutamate receptors, PKC and PKA participate in CAT's antinociceptive mechanism.


Subject(s)
Acid Sensing Ion Channels/drug effects , Acute Pain/drug therapy , Analgesics/pharmacology , Monoterpenes/pharmacology , Nociceptive Pain/drug therapy , TRPV Cation Channels/drug effects , Acetic Acid/toxicity , Acid Sensing Ion Channels/metabolism , Acute Pain/chemically induced , Acute Pain/metabolism , Administration, Oral , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Exploratory Behavior/drug effects , Extremities/pathology , Formaldehyde/toxicity , Male , Mice , Motor Activity/drug effects , Nociceptive Pain/chemically induced , Nociceptive Pain/metabolism , Pain Measurement , Rotarod Performance Test , TRPV Cation Channels/metabolism
5.
Naunyn Schmiedebergs Arch Pharmacol ; 384(6): 525-33, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21870032

ABSTRACT

(-)-α-Bisabolol is an unsaturated, optically active sesquiterpene alcohol obtained by the direct distillation of essential oil from plants such as Vanillosmopsis erythropappa and Matricaria chamomilla. (-)-α-Bisabolol has generated considerable economic interest, as it possesses a delicate floral odour and has been shown to have antiseptic and gastroprotective activities. In this study, (-)-α-bisabolol was tested in standardised rodent models by gavage administration at doses of 100 and 200 mg/kg in the models of inflammation and 25 and 50 mg/kg in the models of nociception. In the inflammatory models of paw oedema induced by carrageenan and dextran, the mice treated with (-)-α-bisabolol showed smaller oedemas compared to animals treated only with the vehicle. (-)-α-Bisabolol was capable of reducing paw oedemas induced by 5-HT but not oedemas induced by histamine. (-)-α-Bisabolol demonstrated anti-nociceptive activity in the models of visceral nociception induced by acetic acid and in the second phase of the nociception test induced by the intraplantar administration of formalin. (-)-α-Bisabolol did not have any effect in a thermal nociception model using a hot plate but was able to diminish mechanical inflammatory hypernociception evoked by carrageenan. These findings suggest that the anti-nociceptive action of (-)-α-bisabolol is not linked to a central mechanism but instead is related to the inflammatory process. (-)-α-Bisabolol was able to decrease leukocyte migration, protein extravasations and the amount of TNF-α to the peritoneal cavity in response to carrageenan. Additionally, (-)-α-bisabolol reduced neutrophil degranulation in response to phorbol-myristate-acetate. We demonstrate, for the first time, the peripheral anti-inflammatory and anti-nociceptive activities of (-)-α-bisabolol.


Subject(s)
Inflammation/drug therapy , Pain/drug therapy , Sesquiterpenes/pharmacology , Analgesics/administration & dosage , Analgesics/pharmacology , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/pharmacology , Disease Models, Animal , Dose-Response Relationship, Drug , Edema/drug therapy , Edema/physiopathology , Inflammation/physiopathology , Male , Mice , Monocyclic Sesquiterpenes , Neutrophils/drug effects , Neutrophils/metabolism , Pain/physiopathology , Rats , Sesquiterpenes/administration & dosage , Tetradecanoylphorbol Acetate/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL